See more : Aravive, Inc. (ARAV) Income Statement Analysis – Financial Results
Complete financial analysis of Celldex Therapeutics, Inc. (CLDX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Celldex Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China Southern Airlines Company Limited (ZNH) Income Statement Analysis – Financial Results
- Toray Industries, Inc. (3402.T) Income Statement Analysis – Financial Results
- Hosken Consolidated Investments Limited (HCI.JO) Income Statement Analysis – Financial Results
- Bookoff Group Holdings Limited (9278.T) Income Statement Analysis – Financial Results
- TTY Biopharm Company Limited (4105.TWO) Income Statement Analysis – Financial Results
Celldex Therapeutics, Inc. (CLDX)
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.88M | 2.36M | 4.65M | 7.42M | 3.57M | 9.54M | 12.74M | 6.79M | 5.48M | 3.59M | 4.11M | 11.20M | 9.27M | 46.79M | 15.18M | 7.46M | 5.10M | 4.93M | 3.09M | 6.86M | 4.63M | 6.70M | 3.35M | 763.20K | 1.48M | 2.20M | 1.20M | 1.10M | 4.00M | 7.00M | 9.00M | 6.60M | 10.20M | 10.90M | 7.80M | 4.60M | 2.20M | 100.00K |
| Cost of Revenue | 3.01M | 1.40M | 3.07M | 42.53M | 42.67M | 66.45M | 96.17M | 102.03M | 4.01M | 101.88M | 2.33M | 10.78M | 9.12M | 12.08M | 8.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 41.00K | 36.80K | -689.30K | -712.80K | -400.00K | -300.00K | -100.00K | 1.20M | 1.20M | 1.50M | 600.00K | 1.10M | 800.00K | 800.00K | 300.00K | -100.00K | 0.00 |
| Gross Profit | 3.88M | 957.00K | 1.58M | -35.12M | -39.10M | -56.91M | -83.43M | -95.24M | 1.47M | -98.30M | 1.78M | 427.00K | 146.00K | 34.72M | 6.78M | 7.46M | 5.10M | 4.93M | 3.09M | 6.86M | 4.63M | 6.66M | 3.31M | 1.45M | 2.20M | 2.60M | 1.50M | 1.20M | 2.80M | 5.80M | 7.50M | 6.00M | 9.10M | 10.10M | 7.00M | 4.30M | 2.30M | 100.00K |
| Gross Profit Ratio | 56.30% | 40.60% | 34.04% | -473.39% | -1,094.29% | -596.68% | -654.70% | -1,403.48% | 26.81% | -2,741.08% | 43.23% | 3.81% | 1.58% | 74.19% | 44.68% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 99.39% | 98.90% | 190.32% | 148.05% | 118.18% | 125.00% | 109.09% | 70.00% | 82.86% | 83.33% | 90.91% | 89.22% | 92.66% | 89.74% | 93.48% | 104.55% | 100.00% |
| Research & Development | 118.01M | 82.26M | 53.31M | 42.53M | 42.67M | 66.45M | 96.17M | 102.73M | 100.17M | 104.38M | 67.40M | 47.40M | 32.44M | 27.65M | 26.17M | 26.35M | 18.50M | 18.07M | 14.06M | 13.87M | 10.02M | 14.71M | 21.58M | 10.77M | 7.87M | 5.70M | 5.30M | 6.00M | 8.00M | 8.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 30.91M | 27.20M | 20.49M | 14.46M | 15.43M | 19.27M | 25.00M | 35.98M | 33.84M | 20.62M | 14.81M | 10.02M | 9.24M | 10.43M | 17.12M | 14.75B | 8.50B | 0.00 | 6.89B | 0.00 | 0.00 | 0.00 | 4.91M | 4.81M | 4.28M | 3.80M | 3.50M | 6.50M | 5.90M | 5.80M | 16.00M | 0.00 | 12.90M | 11.50M | 8.30M | 6.10M | 3.70M | 1.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -14.73B | -8.49B | 0.00 | -6.89B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.91M | 27.20M | 20.49M | 14.46M | 15.43M | 19.27M | 25.00M | 35.98M | 33.84M | 20.62M | 14.81M | 10.02M | 9.24M | 10.43M | 17.12M | 14.75M | 8.50M | 8.24M | 6.89M | 5.57M | 5.35M | 5.59M | 4.91M | 4.81M | 4.28M | 3.80M | 3.50M | 6.50M | 5.90M | 5.80M | 16.00M | 10.10M | 12.90M | 11.50M | 8.30M | 6.10M | 3.70M | 1.90M |
| Other Expenses | 12.50M | 90.34M | 55.38M | 54.02M | 42.71M | 224.00K | 896.00K | 997.00K | 1.01M | 1.01M | 1.01M | 1.09M | 1.91M | 3.14M | 345.00K | 361.01K | 960.21K | 995.11K | 995.11K | 995.10K | 995.10K | 795.10K | 1.38M | 1.31M | 1.99M | 1.00M | 400.00K | 500.00K | 700.00K | 800.00K | 900.00K | 600.00K | 600.00K | 500.00K | 300.00K | 200.00K | 200.00K | 100.00K |
| Operating Expenses | 161.43M | 109.45M | 73.80M | 56.99M | 58.10M | 85.94M | 122.07M | 139.70M | 135.02M | 126.02M | 83.22M | 58.50M | 43.60M | 41.17M | 43.63M | 41.46M | 27.96M | 27.30M | 21.95M | 20.44M | 16.37M | 21.10M | 27.87M | 16.89M | 14.14M | 10.50M | 9.20M | 13.00M | 14.60M | 15.30M | 16.90M | 10.70M | 13.50M | 12.00M | 8.60M | 6.30M | 3.90M | 2.00M |
| Cost & Expenses | 161.43M | 109.45M | 73.80M | 56.99M | 58.10M | 85.94M | 122.07M | 139.70M | 135.02M | 126.02M | 85.55M | 69.28M | 52.71M | 53.25M | 52.03M | 41.46M | 27.96M | 27.30M | 21.95M | 20.44M | 16.37M | 21.14M | 27.91M | 16.20M | 13.43M | 10.10M | 8.90M | 12.90M | 15.80M | 16.50M | 18.40M | 11.30M | 14.60M | 12.80M | 9.40M | 6.60M | 3.80M | 2.00M |
| Interest Income | 13.11M | 0.00 | 505.00K | 2.41M | 4.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 530.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 151.09M | 15.97M | 0.00 | 0.00 | 0.00 | 927.00K | 1.58M | 1.80M | 1.34M | 452.00K | 156.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.01M | 1.40M | 3.07M | 2.00M | 4.86M | 3.80M | 5.31M | 4.09M | 1.01M | 1.01M | 2.95M | 1.09M | 1.91M | 3.14M | 3.53M | 2.54M | 2.69M | 2.10M | 2.13M | 1.72M | 1.53M | 1.62M | 2.26M | 1.31M | 1.99M | 1.00M | 400.00K | 500.00K | 700.00K | 800.00K | 900.00K | 600.00K | 600.00K | 500.00K | 300.00K | 200.00K | 200.00K | 100.00K |
| EBITDA | -139.03M | -104.20M | -66.08M | -45.64M | -49.67M | -72.60M | -104.02M | -124.44M | -125.53M | -116.53M | -77.68M | -54.41M | -38.84M | 4.67M | -33.07M | -44.96M | -19.07M | -18.16M | -16.50M | -11.82M | -10.21M | -12.81M | -22.30M | -14.13M | -9.96M | -6.95M | -7.31M | -11.30M | -11.10M | -8.70M | -8.50M | -4.10M | -5.90M | -3.80M | -1.40M | -1.30M | -1.80M | -1.40M |
| EBITDA Ratio | -2,019.96% | -4,321.89% | -1,452.55% | -514.92% | -1,628.10% | -6.66% | -753.60% | -2,008.62% | -2,388.18% | -3,385.86% | -1,909.44% | -508.72% | -453.12% | -7.08% | -219.49% | -240.92% | -416.70% | -453.96% | -566.77% | -178.53% | -225.49% | -200.04% | -720.66% | -995.26% | -713.91% | 1,677.27% | -150.00% | -1,118.18% | -367.50% | -94.29% | -107.78% | -74.24% | -46.08% | -20.18% | -25.64% | -56.52% | -104.55% | -1,900.00% |
| Operating Income | -154.54M | -115.23M | -71.24M | -63.35M | -55.03M | -156.44M | -121.53M | -132.92M | -129.54M | -122.43M | -81.44M | -58.08M | -43.40M | -6.46M | -36.85M | -48.76M | -22.85M | -22.37M | -18.87M | -13.58M | -11.73M | -14.43M | -24.56M | -15.44M | -11.94M | -7.90M | -7.70M | -11.80M | -11.80M | -9.50M | -9.40M | -4.70M | -4.40M | -1.90M | -1.60M | -2.00M | -1.60M | -1.90M |
| Operating Income Ratio | -2,245.27% | -4,889.01% | -1,531.78% | -854.06% | -1,540.19% | -1,640.13% | -953.68% | -1,958.68% | -2,363.89% | -3,414.11% | -1,981.08% | -518.45% | -468.42% | -13.79% | -242.75% | -653.96% | -447.88% | -453.60% | -610.85% | -198.03% | -253.28% | -215.25% | -734.07% | -2,023.17% | -805.14% | -359.09% | -641.67% | -1,072.73% | -295.00% | -135.71% | -104.44% | -71.21% | -43.14% | -17.43% | -20.51% | -43.48% | -72.73% | -1,900.00% |
| Total Other Income/Expenses | 13.11M | 2.91M | 505.00K | 2.41M | 4.15M | 4.49M | 4.21M | 4.39M | 2.34M | 4.35M | -108.00K | -1.05M | -1.35M | 3.92M | -4.20M | 1.26M | -6.25M | 2.11M | 768.45K | 378.60K | 239.80K | 602.70K | 1.81M | -6.53M | 635.20K | 49.60K | -5.50M | 1.00M | 3.60M | -2.10M | 1.20M | 800.00K | 3.00M | 3.30M | 1.00M | 800.00K | 1.30M | 100.00K |
| Income Before Tax | -141.43M | -112.33M | -70.74M | -60.95M | -50.88M | -151.95M | -117.31M | -128.53M | -127.20M | -118.08M | -81.55M | -59.12M | -44.80M | -2.53M | -37.05M | -62.26M | -21.76M | -20.25M | -18.10M | -13.20M | -11.49M | -13.83M | -22.75M | -21.98M | -11.31M | -7.90M | -13.20M | -10.80M | -8.20M | -11.60M | -8.20M | -3.90M | -3.50M | -1.10M | -900.00K | -1.20M | -700.00K | -1.80M |
| Income Before Tax Ratio | -2,054.76% | -4,765.59% | -1,520.92% | -821.61% | -1,423.96% | -1,593.09% | -920.61% | -1,894.05% | -2,321.11% | -3,292.81% | -1,983.70% | -527.79% | -483.53% | -5.41% | -244.10% | -835.04% | -426.40% | -410.74% | -585.96% | -192.51% | -248.10% | -206.26% | -680.03% | -2,879.32% | -762.33% | -359.09% | -1,100.00% | -981.82% | -205.00% | -165.71% | -91.11% | -59.09% | -34.31% | -10.09% | -11.54% | -26.09% | -31.82% | -1,800.00% |
| Income Tax Expense | 0.00 | 10.46M | -227.00K | -1.17M | -506.00K | -765.00K | -24.28M | -8.77M | -2.34M | -4.35M | -819.00K | -530.00K | -446.00K | -5.31M | -529.00K | 27.00M | -120.00K | 120.00K | -1.54M | -757.20K | 695.70K | -1.21M | -3.62M | 13.07M | -1.27M | 87.70M | 10.90M | -2.00M | -7.10M | 4.20M | -2.80M | -1.90M | -1.90M | -1.70M | -1.20M | -1.60M | -1.70M | -300.00K |
| Net Income | -141.43M | -122.78M | -70.51M | -59.78M | -50.37M | -151.18M | -93.03M | -128.53M | -127.20M | -118.08M | -81.55M | -59.12M | -44.80M | -2.53M | -36.53M | -47.50M | -21.64M | -20.37M | -18.10M | -13.20M | -12.67M | -13.83M | -22.75M | -21.98M | -11.31M | -51.80M | -13.10M | -10.80M | -8.30M | -11.60M | -7.80M | -3.60M | -3.40M | -1.00M | -1.10M | -1.20M | -800.00K | -1.70M |
| Net Income Ratio | -2,054.76% | -5,209.29% | -1,516.04% | -805.88% | -1,409.80% | -1,585.07% | -730.06% | -1,894.05% | -2,321.11% | -3,292.81% | -1,983.70% | -527.79% | -483.53% | -5.41% | -240.61% | -637.12% | -424.05% | -413.17% | -585.96% | -192.51% | -273.47% | -206.26% | -680.03% | -2,879.32% | -762.33% | -2,354.55% | -1,091.67% | -981.82% | -207.50% | -165.71% | -86.67% | -54.55% | -33.33% | -9.17% | -14.10% | -26.09% | -36.36% | -1,700.00% |
| EPS | -2.92 | -2.62 | -1.64 | -2.02 | -3.47 | -14.48 | -10.86 | -18.99 | -19.66 | -19.81 | -15.33 | -15.37 | -17.01 | -1.19 | -27.64 | -50.12 | -468.75 | -49.41 | -43.93 | -32.57 | -36.48 | -41.17 | -70.63 | -75.43 | -46.18 | -281.04 | -89.06 | -89.61 | -85.46 | -122.55 | -82.48 | -48.26 | -57.95 | -18.89 | -23.80 | -26.22 | -17.49 | -37.21 |
| EPS Diluted | -2.92 | -2.62 | -1.64 | -2.02 | -3.47 | -14.48 | -10.86 | -18.99 | -19.66 | -19.81 | -15.33 | -15.37 | -17.01 | -1.19 | -27.64 | -50.12 | -468.75 | -49.41 | -43.93 | -32.57 | -36.48 | -41.17 | -70.63 | -75.43 | -46.18 | -281.04 | -89.06 | -89.61 | -85.46 | -122.55 | -82.48 | -48.26 | -57.95 | -18.89 | -23.80 | -26.22 | -17.49 | -37.21 |
| Weighted Avg Shares Out | 48.45M | 46.89M | 42.87M | 29.64M | 14.51M | 10.44M | 8.57M | 6.77M | 6.47M | 5.96M | 5.32M | 3.85M | 2.63M | 2.12M | 1.32M | 947.80K | 46.16K | 412.31K | 411.91K | 405.36K | 347.29K | 335.90K | 322.12K | 291.32K | 244.87K | 184.32K | 147.10K | 120.52K | 97.12K | 94.66K | 94.57K | 74.59K | 58.67K | 52.93K | 46.22K | 45.77K | 45.75K | 45.69K |
| Weighted Avg Shares Out (Dil) | 48.45M | 46.89M | 42.87M | 29.64M | 14.51M | 10.44M | 8.57M | 6.77M | 6.47M | 5.96M | 5.32M | 3.85M | 2.63M | 2.12M | 1.32M | 947.80K | 46.16K | 412.31K | 411.91K | 405.36K | 347.29K | 335.90K | 322.12K | 291.32K | 244.87K | 184.32K | 147.10K | 120.52K | 97.12K | 94.66K | 94.57K | 74.59K | 58.67K | 52.93K | 46.22K | 45.77K | 45.75K | 45.69K |
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of 8,520,000 shares of its common stock at a public offering price of $47.00 per...
Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock?
Celldex (CLDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Predict a 26.53% Upside in Celldex (CLDX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 26.5% in Celldex (CLDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an...
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market conditions, $250.0 million of shares of its common stock in an...
Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.56 per share a year ago.
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - -...
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups - - Sustained activity with rapid onset within 2 weeks - - Similar improvement in omalizumab-experienced/refractory and omalizumab-naïve disease...
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
HAMPTON, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 9:00 a.m. ET.
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
HAMPTON, N.J., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing 12 week results from the Company's Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU)...
MoneyShow's Best Investment Ideas For 2024: Part 3
MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed...
Source: https://incomestatements.info
Category: Stock Reports